Among these are BCL2 inhibitors (e.g., venetoclax) and EZH2 inhibitors (e.g., tazemetostat), which have the potential to be also clinically relevant in MM (Tremblay-LeMay et al., 2018; Yap et al., 2019; Gupta et al., 2021). The gene discussed is BCL2; the disease is Miyoshi myopathy.